KNTE

XOMA Corporation Announces Closing of Tender Offer

Retrieved on: 
Wednesday, April 3, 2024
SVB Securities, Health, XRA, Lazard, KNTE, Sale, Expiration, Gibson Dunn, Mergers and acquisitions

The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024 (the “Expiration Date”).

Key Points: 
  • The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Tuesday, April 2, 2024 (the “Expiration Date”).
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.
  • Immediately after the Expiration Date, XOMA irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares.
  • Following the closing of the tender offer, XOMA merged Kinnate with and into a subsidiary, XRA 1 Corp. (the “Merger”), and all shares of Kinnate common stock that had not been validly tendered were converted into the right to receive the Offer Price.

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Retrieved on: 
Tuesday, March 19, 2024
KNTE, Cash, Acquisition, Treasury, Sale, CVR, Security (finance)

On March 4, 2024, XOMA commenced a tender offer to acquire all outstanding shares of Kinnate common stock (“the Offer”).

Key Points: 
  • On March 4, 2024, XOMA commenced a tender offer to acquire all outstanding shares of Kinnate common stock (“the Offer”).
  • Pursuant to the terms of the Merger Agreement, based upon Kinnate’s estimated calculation of cash, net of transaction costs, wind-down costs and other liabilities at closing, the additional cash amount has been determined to be the maximum $0.2527 per share.
  • Therefore, the Cash Amount that Kinnate stockholders will receive in the Offer is $2.5879 per share.
  • As previously announced, Kinnate stockholders holding approximately 46% of Kinnate common stock have signed support agreements to tender their shares in the Offer prior to the expiration date and support the merger.

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – TGAN, HMST, KNTE

Retrieved on: 
Monday, March 18, 2024
Empire, KNTE, Transphorm, Sale, Electronics, Security (finance)

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, TGAN shareholders will receive $5.10 in cash per share they own.
  • Under the terms of the agreement, HMST shareholders are expected to receive 0.4345 shares of FirstSun common stock per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – KNTE, DOOR, HMST

Retrieved on: 
Wednesday, March 13, 2024
Empire, KNTE, Sale, Owens Corning, Security (finance)

Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, DOOR shareholders are expected to receive $133.00 in cash per share they own.
  • Under the terms of the agreement, HMST shareholders are expected to receive 0.4345 shares of FirstSun common stock per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?

KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Retrieved on: 
Wednesday, March 13, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, KNTE, Sale, HireRight

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – BATL, MDC, KNTE, INBX

Retrieved on: 
Thursday, March 7, 2024
KNTE, Empire, Sale, MDC, Sekisui House, CVR, Security (finance)

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, BATL shareholders are expected to receive $9.80 in cash per share they own.
  • Under the terms of the agreement, MDC shareholders are expected to receive $63.00 in cash per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Kinnate Biopharma Inc. by XOMA Corporation

Retrieved on: 
Friday, March 1, 2024
Foresite Capital, Acquisition, KNTE, Person, Telephone, Sale, LLP, OrbiMed

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Kinnate by XOMA Corporation (“XOMA”).

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Kinnate by XOMA Corporation (“XOMA”).
  • As a result of the merger, Kinnate stockholders will receive $2.3352 per share in cash and additional cash up to $0.2527 per share, plus a contingent value right.
  • To learn more about the action and your rights, go to:
    or contact Joseph E. Levi, Esq.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Retrieved on: 
Friday, March 1, 2024
NRAS, BRAF, Acquisition, SAN, KNTE, APA, SAS, Sale, Contingent value rights, RAS, RAF, Patient, Tax, Health care, Development, MEK, Lazard, Melanoma, Pharmaceutical industry

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Key Points: 
  • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
  • In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – KAMN, ERF, DFS, KNTE

Retrieved on: 
Friday, February 23, 2024
KNTE, Financial services, Empire, Capital One, KAMN, Investment management, Discover Financial, Sale, DFS, ERF, Security (finance)

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, KAMN shareholders are expected to receive $46.00 in cash per share they own.
  • Enerplus Corp. (NYSE: ERF ), relating to its proposed merger with Chord Energy Corp.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?

KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE

Retrieved on: 
Monday, February 19, 2024
Legal, Professional Services, KSF, KNTE, HireRight, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .